Zobrazeno 1 - 10 of 82 pro vyhledávání: '"Henry B, Koon"'
1
Akademický článek
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Autor: F Stephen Hodi, Ahmad A Tarhini, John M Kirkwood, Zeynep Eroglu, Henry B Koon, Ni Kang, Vernon K Sondak, Harriet M Kluger, Sandra J Lee, Gary I Cohen, Laura F Hutchins, Donald P Lawrence, Kari L Kendra, David R Minor, Carrie B Lee, Mark R Albertini, Lawrence E Flaherty, Teresa M Petrella
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background The impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood.Patients and method
Externí odkaz: https://doaj.org/article/6f596cfb2e7048f7b2e60a6a21991735
Zobrazit plný text záznamu
2
Akademický článek
Evolving impact of long-term survival results on metastatic melanoma treatment
Autor: Olivier Michielin, Paolo Antonio Ascierto, Reinhard Dummer, Michael B Atkins, Henry B Koon
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Melanoma treatment has been revolutionized over the past decade. Long-term results with immuno-oncology (I-O) agents and targeted therapies are providing evidence of durable survival for a substantial number of patients. These results have prompted c
Externí odkaz: https://doaj.org/article/a49b7694e0104bf78e0be5fb27cb29b2
Zobrazit plný text záznamu
4
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Autor: Shahrokh F. Shariat, Alexander Nosov, Aristotelis Bamias, T. Lebret, Matthew I. Milowsky, Yoshihiko Tomita, Matthew D. Galsky, Dingwei Ye, Begoña P. Valderrama, Deborah Enting, Edward Broughton, Mads Agerbaek, João Neif Antonio, Michael Schenker, Dimitrios Zardavas, Pablo Gajate, Se Hoon Park, Henry B. Koon, Ray McDermott, Krzysztof Tupikowski, Avivit Peer, Bruce S. Fischer, Dean F Bajorin, Keziban Unsal-Kacmaz, J. Alfred Witjes, Laurence Toms, Sandra Collette, Anila Qureshi, Jürgen E. Gschwend
Publikováno v: The New England Journal of Medicine, 384, 22, pp. 2102-2114
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 384 (22), pp.2102-2114. ⟨10.1056/NEJMoa2034442⟩
N Engl J Med
Bajorin, D F, Witjes, J A, Gschwend, J E, Schenker, M, Valderrama, B P, Tomita, Y, Bamias, A, Lebret, T, Shariat, S F, Park, S H, Ye, D, Agerbaek, M, Enting, D, McDermott, R, Gajate, P, Peer, A, Milowsky, M I, Nosov, A, Antonio, J N, Tupikowski, K, Toms, L, Fischer, B S, Qureshi, A, Collette, S, Unsal-Kacmaz, K, Broughton, E, Zardavas, D, Koon, H B & Galsky, M D 2021, ' Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma ', New England Journal of Medicine, vol. 384, no. 22, pp. 2102-2114 . https://doi.org/10.1056/NEJMoa2034442
The New England Journal of Medicine, 384, 2102-2114
BACKGROUND: The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. METHODS: In a phase 3, multicenter, double-blind, randomized, controlled trial, we assigned patients with muscle-invasive
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::606457002294dbe1ff3243ad786b01e3
https://hdl.handle.net/2066/234161
Zobrazit plný text záznamu
5
Akademický článek
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
Autor: Bin Zhang, F. Stephen Hodi, Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy Guthrie, Sajeve S. Thomas, Steven J. O’Day, Montaser F. Shaheen, Stephen Francis
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude concomitant admi
Externí odkaz: https://doaj.org/article/0f77214448854233aa98f583d805a4de
Zobrazit plný text záznamu
7
Immune checkpoint inhibitor-induced sarcoidosis-like granulomas
Autor: Henry B. Koon, Barbara Reichert, Ashley Feneran, Kord Honda, Meg R. Gerstenblith, Pooja H. Rambhia, Jordan Kazakov, Jeffrey F. Scott
Publikováno v: International Journal of Clinical Oncology. 24:1171-1181
Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72242735e3a75c608c35a940212c0cfa
https://doi.org/10.1007/s10147-019-01490-2
Zobrazit plný text záznamu
8
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Autor: David R. Minor, Mark R. Albertini, Gary I. Cohen, Ahmad A. Tarhini, Sandra J. Lee, John M. Kirkwood, Harriet M. Kluger, Howard Streicher, Lawrence E. Flaherty, Henry B. Koon, Carrie B. Lee, Ni Kang, Kari Kendra, Jeffrey A. Sosman, Laura F. Hutchins, Zeynep Eroglu, Teresa M. Petrella, F. Stephen Hodi, Omid Hamid, Donald P. Lawrence, Vernon K. Sondak
Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
BackgroundThe impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood.Patients and methods
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2da6985b0925659134397ffbd1cee236
http://europepmc.org/articles/PMC8108687
Zobrazit plný text záznamu
9
312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition
Autor: Howard Striecher, Gary I. Cohen, Teresa M. Petrella, Kari Kendra, H. Kluger, Sandra J. Lee, Lawrence E. Flaherty, Ni Kang, F. Stephen Hodi, Jeffrey A. Sosman, Omid Hamid, Carrie B. Lee, Laura F. Hutchins, Donald P. Lawrence, Henry B. Koon, Vernon K. Sondak, Mark R. Albertini, John M. Kirkwood, David R. Minor, Zeynep Eroglu, Ahmad A. Tarhini
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Sex differences in tumor immunity and response to immunotherapy were shown in murine models and descriptive analyses from recent clinical trials. Female sex hormones have been implicated in melanoma development and response to systemic the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358ab2ec0b89e8eb146d7fa320650442
https://doi.org/10.1136/jitc-2020-sitc2020.0312
Zobrazit plný text záznamu
10
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors
Autor: Joel N. Saltzman, Joseph A. Bokar, Jennifer R. Eads, John J. Pink, Henry B. Koon, Joseph Gibbons, Yan Xu, Neelesh Sharma, Smitha S. Krishnamurthi, Stanton L. Gerson, Pingfu Fu, Jan H. Beumer, Lisa Rogers, P. Savvides, Afshin Dowlati, Neal J. Meropol, John Riendeau
Publikováno v: Invest New Drugs
PURPOSE: Temozolomide (TMZ) generates DNA adducts that are repaired by direct DNA and base excision repair mechanisms. Methoxyamine (MX, TRC-102) potentiates TMZ activity by binding to apurinic and apyrimidinic (AP) sites after removal of N(3)-methyl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b8ccc1158de36c274731a470f2186c6
https://pubmed.ncbi.nlm.nih.gov/32556884
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje